Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Jonker

Showing results (151-160 of 199) with videos related to

Pageof 20
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 18, 2021
Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancerWim van Boxtel, Maike J M Uijen, Stefanie D Krens, et al.
Journal of Biomolecular NMR|May 14, 2017
Impact of spin label rigidity on extent and accuracy of distance information from PRE dataK A Schnorr, D B Gophane, C Helmling, et al.
Neurology|February 19, 2025
Self-Management Program Improves Participation in Patients With Neuromuscular Disease: A Randomized Controlled TrialYvonne Veenhuizen, Edith H C Cup, Marianne A Jonker, et al.
Neurology|October 2, 2019
Self-management program improves participation in patients with neuromuscular disease: A randomized controlled trialYvonne Veenhuizen, Edith H C Cup, Marianne A Jonker, et al.
FEBS Letters|July 12, 2024
Differential effects of the N-terminal helix of FGF8b on the activity of a small-molecule FGFR inhibitor in cell culture and for the extracellular domain of FGFR3c in solutionKonstantin S Mineev, Bruno Hargittay, Jing Jin, et al.
Head & Neck|January 7, 2020
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study CommenceJanneke C Ham, Esther van Meerten, W Edward Fiets, et al.
Clinical Genetics|September 14, 2018
Phenotype-genotype relations in facioscapulohumeral muscular dystrophy type 1Karlien Mul, Nicol C Voermans, Richard J L F Lemmers, et al.
BMC Cancer|September 20, 2024
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocolJetty A M Weijers, Gerald W Verhaegh, G Lassche, et al.
Genome Research|July 24, 2021
Differences in the number of de novo mutations between individuals are due to small family-specific effects and stochasticityJakob M Goldmann, Juliet E Hampstead, Wendy S W Wong, et al.
The American Journal of Clinical Nutrition|April 4, 2014
Nutrition before, during, and after surgery increases the arginine:asymmetric dimethylarginine ratio and relates to improved myocardial glucose metabolism: a randomized controlled trialMarlieke Visser, Mariska Davids, Hein J Verberne, et al.
Pageof 20

Showing results (151-160 of 199) with videos related to

Sort By:
Pageof 20
European Journal of Cancer (Oxford, England : 1990)|December 18, 2021
Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancerWim van Boxtel, Maike J M Uijen, Stefanie D Krens, et al.
Journal of Biomolecular NMR|May 14, 2017
Impact of spin label rigidity on extent and accuracy of distance information from PRE dataK A Schnorr, D B Gophane, C Helmling, et al.
Neurology|February 19, 2025
Self-Management Program Improves Participation in Patients With Neuromuscular Disease: A Randomized Controlled TrialYvonne Veenhuizen, Edith H C Cup, Marianne A Jonker, et al.
Neurology|October 2, 2019
Self-management program improves participation in patients with neuromuscular disease: A randomized controlled trialYvonne Veenhuizen, Edith H C Cup, Marianne A Jonker, et al.
FEBS Letters|July 12, 2024
Differential effects of the N-terminal helix of FGF8b on the activity of a small-molecule FGFR inhibitor in cell culture and for the extracellular domain of FGFR3c in solutionKonstantin S Mineev, Bruno Hargittay, Jing Jin, et al.
Head & Neck|January 7, 2020
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study CommenceJanneke C Ham, Esther van Meerten, W Edward Fiets, et al.
Clinical Genetics|September 14, 2018
Phenotype-genotype relations in facioscapulohumeral muscular dystrophy type 1Karlien Mul, Nicol C Voermans, Richard J L F Lemmers, et al.
BMC Cancer|September 20, 2024
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocolJetty A M Weijers, Gerald W Verhaegh, G Lassche, et al.
Genome Research|July 24, 2021
Differences in the number of de novo mutations between individuals are due to small family-specific effects and stochasticityJakob M Goldmann, Juliet E Hampstead, Wendy S W Wong, et al.
The American Journal of Clinical Nutrition|April 4, 2014
Nutrition before, during, and after surgery increases the arginine:asymmetric dimethylarginine ratio and relates to improved myocardial glucose metabolism: a randomized controlled trialMarlieke Visser, Mariska Davids, Hein J Verberne, et al.
Pageof 20